BioNTech SE reports beneficial ownership disclosures by Medine GmbH and Prof. Ugur Sahin, M.D. The statement shows Medine GmbH holds 39,218,111 ordinary shares (reported shared voting power) representing 15.5% of the class and Prof. Ugur Sahin, M.D. is reported as beneficial owner of 40,076,320 ordinary shares representing 15.8%.
The percentages are calculated on 252,884,261 ordinary shares outstanding as of March 31, 2026. The filing explains a written arrangement where Prof. Sahin retains voting power over certain shares held by Medine GmbH but not dispositive power; holdings are jointly filed by the two Reporting Persons.
Positive
None.
Negative
None.
Insights
Joint disclosure clarifies voting and dispositive arrangements between a principal and its affiliated entity.
The filing attributes shared voting power of 39,218,111 and describes a written arrangement where Prof. Sahin retains voting power over certain shares held by Medine GmbH. This distinction separates voting control from dispositive authority in the public record.
Future filings may show changes in voting or dispositive power; subsequent amendments will update percentages tied to the issuer's outstanding share count.
Prof. Sahin's reported total beneficial ownership is 40,076,320 shares (15.8% of class).
The schedule lists 858,209 shares with sole voting and dispositive power attributed directly to Prof. Sahin and 39,111,390 shares held by Medine GmbH with shared dispositive power. The filing follows Rule 13d-1(k)(1) joint filing mechanics.
Stake size is anchored to the stated March 31, 2026 outstanding base of 252,884,261 shares; cash-flow treatment or transfers are not described in the excerpt.
Key Figures
Shares outstanding:252,884,261 sharesProf. Ugur Sahin beneficial ownership:40,076,320 sharesMedine GmbH voting power:39,218,111 shares+2 more
5 metrics
Shares outstanding252,884,261 sharesas of March 31, 2026
Prof. Ugur Sahin beneficial ownership40,076,320 sharesreported beneficial ownership in Schedule 13G/A
Medine GmbH voting power39,218,111 sharesshared voting power reported
Medine GmbH dispositive power39,111,390 sharesshared dispositive power reported
Prof. Sahin sole voting/dispositive858,209 sharesshares with sole voting and dispositive power
Key Terms
Schedule 13G/A, beneficially owned, shared dispositive power
3 terms
Schedule 13G/Aregulatory
"This Amendment No. 6 to is being jointly filed by Medine GmbH and Prof. Ugur Sahin"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficially ownedfinancial
"Amount beneficially owned: See the responses to Item 9 on the attached cover pages"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive powerfinancial
"Shared Dispositive Power 39,111,390.00"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Prof. Ugur Sahin report in BioNTech (BNTX)?
Prof. Ugur Sahin is reported as beneficial owner of 40,076,320 shares, representing 15.8% of the class based on 252,884,261 shares outstanding as of March 31, 2026. The filing attributes both sole and shared powers across holdings.
How many shares does Medine GmbH hold in BioNTech (BNTX)?
Medine GmbH is reported with shared voting power over 39,218,111 shares and shared dispositive power over 39,111,390 shares, representing 15.5% of the class on the disclosed outstanding base of 252,884,261 shares.
What is the outstanding share base used to calculate percentages in the filing?
The percentages are calculated using 252,884,261 ordinary shares outstanding as of March 31, 2026, as stated in the Schedule 13G/A excerpt provided by the Reporting Persons.
Does the filing explain the relationship between Prof. Sahin and Medine GmbH?
Yes. The filing states a written arrangement where Prof. Sahin retains voting power over certain shares held by Medine GmbH but not dispositive power; both parties jointly filed this Schedule 13G/A.
Are any shares reported as solely dispositive by Prof. Sahin?
The filing shows Prof. Sahin has 858,209 shares of sole dispositive power and sole voting power; larger holdings are reported as shared dispositive or voting power with Medine GmbH.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 6)
BioNTech SE
(Name of Issuer)
Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)
(Title of Class of Securities)
09075V102
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
09075V102
1
Names of Reporting Persons
Medine GmbH
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
GERMANY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
39,218,111.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
39,111,390.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
39,218,111.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
15.5 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Item 9: Consists of 39,111,390 ordinary shares held by Medine GmbH and 106,721 ordinary shares held by a former colleague, over which shares Prof. Ugur Sahin, M.D. retains voting power pursuant to a written arrangement. Pursuant to this arrangement, Prof. Ugur Sahin, M.D. retains voting power, but not dispositive power, over such shares, and accordingly Medine GmbH and Prof. Ugur Sahin, M.D. each may be deemed beneficially to own such shares.
SCHEDULE 13G
CUSIP Number(s):
09075V102
1
Names of Reporting Persons
Ugur Sahin
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TURKEY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
858,209.00
6
Shared Voting Power
39,218,111.00
7
Sole Dispositive Power
858,209.00
8
Shared Dispositive Power
39,111,390.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
40,076,320.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
15.8 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Item 6: Consists of 39,111,390 ordinary shares held by Medine GmbH, 858,209 ordinary shares held by Prof. Ugur Sahin, M.D., and 106,721 ordinary shares held by a former colleague, over which shares Prof. Ugur Sahin, M.D. retains voting power pursuant to a written arrangement. Pursuant to this arrangement, Prof. Ugur Sahin, M.D. retains voting power, but not dispositive power, over such shares, and accordingly Medine GmbH and Prof. Ugur Sahin, M.D. each may be deemed beneficially to own such shares.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BioNTech SE
(b)
Address of issuer's principal executive offices:
An der Goldgrube 12, Mainz, Germany, 55131
Item 2.
(a)
Name of person filing:
This Amendment No. 6 to Schedule 13G is being jointly filed by Medine GmbH and Prof. Ugur Sahin, M.D., each of the foregoing, a "Reporting Person," and together, the "Reporting Persons".
The Reporting Persons have entered into a Joint Filing Agreement, dated February 13, 2020, a copy of which is incorporated by reference herein to Exhibit on the Schedule 13G filed on February 13, 2020, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is Philipp-von-Zabern-Platz 1, D-55116 Mainz, Germany.
(c)
Citizenship:
Medine GmbH is a German limited liability company (Gesellschaft mit beschrankter Haftung). Prof. Ugur Sahin, M.D. is a citizen of Turkey.
(d)
Title of class of securities:
Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)
(e)
CUSIP No.:
09075V102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See the responses to Item 9 on the attached cover pages.
(b)
Percent of class:
See the responses to Item 11 on the attached cover pages, which were calculated based on 252,884,261 ordinary shares of the Issuer outstanding as of March 31, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See the responses to Item 5 on the attached cover pages.
(ii) Shared power to vote or to direct the vote:
See the responses to Item 6 on the attached cover pages.
(iii) Sole power to dispose or to direct the disposition of:
See the responses to Item 7 on the attached cover pages.
(iv) Shared power to dispose or to direct the disposition of:
See the responses to Item 8 on the attached cover pages.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See responses to Item 2(a) and Item 4.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See responses to Item 2(a) and Item 4.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
